ArticleFrontiers in endocrinology2024
Association between neutrophil-to-lymphocyte ratio and left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Precision medicine and personalized nursing in cardiovascular disease: clinical applications and frontier developments.Frontiers in cardiovascular medicine · 2026Review
- Neutrophil-to-Lymphocyte Ratio and Fibroblast Growth Factor 21: Their Role in Early Cardiovascular Involvement in Rheumatoid Arthritis.Journal of clinical medicine · 2025Article
- Age-Related Characteristics of Diastolic Dysfunction in Type 2 Diabetes Patients.Journal of clinical medicine · 2025Article
- The need to redefine diabetic cardiomyopathy as a unique clinical entity that requires pharmacotherapy.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes has become a global pandemic, posing a sustained threat to human health, primarily due to its associated complications. Left ventricular diastolic dysfunction (LVDD) is a prevalent cardiac complication among patients with diabetes. Since most patients are asymptomatic and lack relevant biomarkers, LVDD has not attracted significant attention from clinicians. The neutrophil-to-lymphocyte ratio (NLR) is a widely studied inflammation biomarker that has been suggested to be linked to various medical conditions, including cardiac diseases. However, its association with LVDD among patients with type 2 diabetes mellitus (T2DM) has not been explored. Aim: To clarify the relationship between NLR and LVDD among patients with type 2 diabetes. Methods: We conducted a cross-sectional study using medical records from 855 patients diagnosed with T2DM who were admitted to the Endocrinology department at Wuhan Union Hospital. According to the ASE/EACVI 2016 recommendations, these patients were categorized into two groups based on sonographic parameters: patients with normal left ventricular diastolic function (the non-LVDD group) and patients with LVDD (the LVDD group). NLR values were calculated and divided into three different levels. Statistical analysis was conducted to evaluate the correlation between NLR levels and the prevalence of LVDD. Results: The prevalence of LVDD among hospitalized patients with T2DM in our study was 47.8% (409/855). The mean NLR value of the LVDD group was significantly higher compared with the non-LVDD group [1.60 (1.24-2.05) vs 1.85 (1.44-2.31), P<0.001]. The prevalence of LVDD in the three different NLR levels was 35.51% (76/214), 49.27% (203/412), and 56.77% (130/229), respectively. Unjustified logistic analysis showed that NLR levels were positively associated with the prevalence of LVDD (P <0.001). Compared to the low level of NLR, the unadjusted odds ratios (OR) of LVDD at the medium and high levels were 1.764 (1.255-2.478, P=0.001) and 2.384 (1.626-3.497, P<0.001), respectively (P for trend <0.001). Conclusion: Our findings suggest that the NLR is a potential indicator for assisting clinicians in identifying LVDD in patients with T2DM. Patients with elevated NLR levels may be at a greater risk of developing LVDD than those with lower NLR levels, which may require attention and interventions to prevent patients from progressing into heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.